Actavis Completes Sales Reorganization, Pipeline Rationalization
This article was originally published in The Pink Sheet Daily
The company will move forward with 70 pipeline candidates following the closing of the Allergan merger, Senior VP-Brand R&D David Nicholson said during the company’s first quarter earnings call.
You may also be interested in...
The growing spec pharma has seen a 300% increase in its branded portfolio revenues since the acquisition of Forest and Warner Chilcott and is honoring the new direction by taking on the name of its most recent acquisition.
New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.